TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33789251
Drug: Anthocyanins (AC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins (AC) 320 mg/day in the form of Medox® capsules for 28 days
Study: 33882052
Drug: Daily e-cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily e-cigarette use
Study: 33882052
Drug: Daily heated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily heated tobacco use
Study: 33882052
Drug: Odds of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odds of daily cigarette smoking
Study: 33882052
Drug: Odds of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odds of daily heated tobacco use
Study: 36585491
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (ET)
Study: 35343187
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg
Study: 35286913
Drug: MW032 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: MW032 (120 mg)
Study: 34959872
Drug: O2-water enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2-water enriched by injection (110 mg O2·L-1)
Study: 34959872
Drug: O2-water enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2-water enriched by electrolysis (110 mg O2·L-1)
Study: 34959872
Drug: Placebo water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo water (10 mg O2·L-1)
Study: 33862286
Drug: Task-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-based training along with conventional therapy
Study: 32753637
Drug: L-Theanine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Theanine (2.5 mg/kg)
Study: 32753637
Drug: Caffeine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2.0 mg/kg)
Study: 32753637
Drug: L-Theanine-caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Theanine-caffeine combination
Study: 36150238
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (2.5 mL orally every 8 hours for 1 month)
Study: 35430674
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin treatment with fasting blood glucose (FBG) target of > 3.9 to ≤ 5.6 mmol/L
Study: 35430674
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin treatment with fasting blood glucose (FBG) target of > 3.9 to ≤ 6.1 mmol/L
Study: 35430674
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin treatment with fasting blood glucose (FBG) target of > 3.9 to ≤ 7.0 mmol/L
Study: 35430674
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin treatment
Study: 32224987
Drug: Tryptophan and
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan and magnesium-enriched Mediterranean diet (60 mg of TRY and 60 mg of MG)
Study: 38631835
Drug: Stimulant
Normalized name: Stimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant
Study: 34049443
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine collaborative model of care (TCMCMC) with acupuncture
Study: 35799299
Drug: Antenatal milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal milk expression (AME) intervention involving technique demonstration and feedback from a lactation consultant, daily independent practice, delivered at weekly visits at 37-40 weeks of pregnancy.
Study: 33879065
Drug: Internet-based behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based behavioural activation (iBA) therapy, 12 weekly sessions with online assignments and feedback from trained therapists.
Study: 33879065
Drug: Internet-based behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based behavioural activation (iBA) therapy
Study: 32196826
Drug: Altered fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altered fractionation (AF) - 1.1 Gy + 2 Gy/d, 5 d/wk, 4.5 weeks, total dose 68 Gy
Study: 32196826
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (CF) - 2 Gy/d, 5 d/wk, 7 weeks, total dose 68 Gy
Study: 34733978
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment applied at Baihui (GV20), Yintang (GV29), Shenmen (HT7, bilateral), and Sanyinjiao (SP6, bilateral) 3 times a week for 4 weeks.
Study: 33706653
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (SC‐I)
Study: 33706653
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (IV‐I)
Study: 32324850
Drug: Community-based mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based mass testing and treatment (MTaT) performed 3 times per year for 2 years.
Study: 32324850
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard of care for testing and treatment at public health facilities along with government‐sponsored mass long‐lasting insecticidal net [LLIN] distributions).
Study: 33793580
Drug: União Química
Approvals — FDA: no, EMA: no, PMDA: no
Description: União Química generic warfarin
Study: 33793580
Drug: Teuto generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teuto generic warfarin
Study: 36057254
Drug: Square-stepping exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Square-stepping exercise (SSE), 8 weeks, twice a week
Study: 33415872
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) applied at Zusanli (ST 36), Xuehai (SP 10), Sanyinjiao (SP 6) for 30 min each time, twice daily for 5 days.
Study: 33415872
Drug: Conventional nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional nursing combined with early functional exercise (20 min each time, twice daily for 5 days).
Study: 33415872
Drug: Rehabilitation training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation training (20 min each time, twice daily for 5 days).
Study: 33098678
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation (HDR, 45 + 18 Gy)
Study: 33098678
Drug: Radiochemotherapy (RCT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiochemotherapy (RCT, 45 Gy + 5FU infusion)
Study: 35571974
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT), provided monthly for up to six months
Study: 35201924
Drug: Foot reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot reflexology (30 minutes twice per week for 6 weeks)
Study: 35349976
Drug: High-dose minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose minocycline (10 mg/kg)
Study: 35349953
Drug: PIO-5 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIO-5 (5 mg PIO/bird/day)
Study: 35349953
Drug: PIO-10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIO-10 (10 mg PIO/bird/day)
Study: 36415112
Drug: Berberine triple
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine triple therapy (berberine, amoxicillin, rabeprazole)
Study: 36415112
Drug: Standard bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bismuth quadruple therapy (amoxicillin, rabeprazole, clarithromycin, bismuth tartrate)
Study: 32654080
Drug: All urate-lowering
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All urate-lowering therapies (ULTs)
Study: 32654080
Drug: Febuxostat 80/120/240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80/120/240 mg/day
Study: 32654080
Drug: Lesinurad in
Normalized name: Product containing lesinurad in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad in combination with febuxostat or allopurinol
Study: 34636463
Drug: Djulis functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Djulis functional drinks (50 ml daily for 8 weeks)
Study: 34636463
Drug: Placebo drinks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drinks (50 ml daily for 8 weeks)
Study: 34103473
Drug: High-dose hUC-MSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hUC-MSC (1.5 × 10^6/kg body weight)
Study: 34103473
Drug: Low-dose hUC-MSC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hUC-MSC (0.5 × 10^6/kg body weight)
Study: 34103473
Drug: Low-dose hUC-MSC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hUC-MSC
Study: 32333337
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBM) - 24 sessions, 810 nm, 5 diodes × 200 mW, 30 J/application site
Study: 32333337
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - no physical therapy intervention, only underwent hemodialysis (HD) sessions
Study: 35030634
Drug: Historical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical treatments (CORAL study)
Study: 36480560
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg/day) for 6 months
Study: 35610318
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion with loading dose group (GpIII)
Study: 35610318
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion without loading dose group (GpII)
Study: 34243738
Drug: PathMate2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PathMate2 group (PM) - daily conversational agent counselling via mobile app, combined with standardized counselling (4 on-site visits) for 5.5 months.
Study: 33278291
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine with 4 mg dexamethasone
Study: 36414947
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (1000 mg natural fish oil soft-gels daily for 3 months)
Study: 36414947
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil soft-gels (control group)
Study: 34694261
Drug: Dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium channel blockers (CCB)
Study: 33954933
Drug: Oral abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral abrocitinib 200 mg
Study: 33954933
Drug: Oral abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral abrocitinib 100 mg
Study: 32172686
Drug: Spiritual coping
Normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spiritual coping through adherence measures (interview or daily phone diary)
Study: 32481332
Drug: Tong Jing
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tong Jing Tiao Xing tuina (TJTX) once a day, Excising with scalp acupuncture (ESA) once a day, and oral Yinao fujian formula (YNFJ) twice a day for 5 sessions a week for 4 weeks.
Study: 32481332
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) for 5 sessions a week for 4 weeks.
Study: 33922576
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose strawberry powder (32 g/day)
Study: 33922576
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose strawberry powder (13 g/day)
Study: 32004568
Drug: Bermekimab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bermekimab (400 mg weekly for 13 doses) in anti-TNF naïve patients (n = 18)
Study: 32004568
Drug: Bermekimab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bermekimab (400 mg weekly for 13 doses) in patients who failed anti-TNF therapy (n = 24)
Study: 35580634
Drug: Oral phenazopyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phenazopyridine (200 mg taken 1 to 2 hours preprocedure)
Study: 35580634
Drug: Intravesical lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical lidocaine (20-minute instillation of 50 mL of 2% lidocaine)
Study: 32141476
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bip.App and Group PE
Study: 35802142
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg OD
Study: 33827421
Drug: Concurrent magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent magnesium with sodium valproate (group B)
Study: 36038015
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.2 mg nicotine/cigarette)
Study: 36038015
Drug: Usual Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual Nicotine Content (UNC) cigarettes (11.6 mg nicotine/cigarette)
Study: 35759325
Drug: Therapeutic adherence
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic adherence and competence scale for grief (TACs-G)
Study: 32365981
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299v with 20 mg of iron
Study: 32365981
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of iron alone
Study: 35761383
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg per os 2 hours before surgery
Study: 35761383
Drug: Starch tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch tablet per os 2 hours before surgery (control group)
Study: 32197636
Drug: Adjunct low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunct low-dose continuous infusion of ketamine (2 μg/kg/min for the first 24 hours, then 1 μg/kg/min for the second 24 hours) plus standard of care.
Study: 36134443
Drug: App-guided fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-guided fluid therapy calculations
Study: 36134443
Drug: App-guided integrated
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: App-guided integrated fluid therapy plans
Study: 32858228
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids 1000 mg/day (EPA+DHA, ratio 1:2)
Study: 38804148
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg per day
Study: 32527389
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose of .04 g/dl
Study: 32527389
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose of .065 g/dl
Study: 32527389
Drug: Alcohol doses
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol doses (.04 g/dl and .065 g/dl)
Study: 36328822
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy
Study: 33317481
Drug: Health qigong-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health qigong-based cognitive therapy
Study: 37393402
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg (with 300 mg loading dose) for 24 weeks
Study: 37393402
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg (with 300 mg loading dose) for 12 weeks then bepirovirsen 150 mg for 12 weeks
Study: 37393402
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg (with 300 mg loading dose) for 12 weeks then placebo for 12 weeks
Study: 37393402
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks (with placebo loading dose) then bepirovirsen 300 mg without loading dose for 12 weeks
Study: 86099028
Drug: D-penicillamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine and prednisone (low-dose combination therapy)
Study: 32091466
Drug: Daily nonlinear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nonlinear periodization (NLP)
Study: 32091466
Drug: Flexible daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible daily nonlinear periodization (FNLP)
Study: 33566465
Drug: Enoxaparin started
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin started less than 24 hours after insertion of central venous catheter, adjusted to anti-Xa level of 0.2–0.5 international units/mL
Study: 32169923
Drug: Standardised self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised self-management kits and Usual treatment (Control)
Study: 32960464
Drug: G‐MEDSS with
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐MEDSS with usual care HMR
Study: 32574657
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention (four sessions)
Study: 32557974
Drug: HDM sublingual
Normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM sublingual immunotherapy (SLIT)
Study: 33832089
Drug: COPD medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD medical treatment + KT (Group 1)
Study: 33832089
Drug: COPD medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD medical treatment alone (Group 2)
Study: 32376313
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of an intrauterine device (IUD) with a Foley catheter after hysteroscopic adhesiolysis
Study: 34955257
Drug: Low compound
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low compound probiotics (0.12 g per head per day)
Study: 34955257
Drug: High compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: High compound probiotics (1.2 g per head per day)
Study: 34955257
Drug: Compound probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound probiotics (both low and high)
Study: 34955257
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (milk replacer with no compound probiotics)
Study: 32910710
Drug: Continuous nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nivolumab (3 mg/kg every 2 weeks)
Study: 36269184
Drug: Repeated low-level
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated low-level red light (RLRL) therapy
Study: 33947856
Drug: PfSPZ vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ vaccine (1.1 × 10^5 aseptic, purified, cryopreserved PfSPZ of the PfNF54 strain) with 10 mg/kg chloroquine base
Study: 33947856
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) with 10 mg/kg chloroquine base
Study: 37790581
Drug: PfSPZ vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ vaccine
Study: 33168081
Drug: Closed incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed incision negative pressure wound therapy (ciNPWT) for 7 days
Study: 34540636
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral medication: cyproterone compound tablets 50 mg BD and diazepam tablets 2 mg TDS for a week)
Study: 37520237
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (control)
Study: 35279214
Drug: D‐SOX group
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐SOX group (intraperitoneal infusion of docetaxel 30 mg/m2 on d1 and d8, intravenous oxaliplatin 100 mg/m2 on d1, and oral administration of S‐1 on d1‐d14)
Study: 35279214
Drug: DOS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOS group (intravenous docetaxel 60 mg/m2 on d1, intravenous oxaliplatin 100 mg/m2 on d1, and oral administration of S‐1 on d1‐d14)
Study: 33761207
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg abrocitinib
Study: 33761207
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg abrocitinib
Study: 32457075
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg)
Study: 32247603
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine (1000 mg/m2 on days 1 and 8 of a 21 day cycle) plus pazopanib (800 mg QD)
Study: 32247603
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine (1000 mg/m2 on days 1 and 8 of a 21 day cycle) alone